Skip to main content

AXCELIS TECHNOLOGIES INC

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

ACLS$107.64+8.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Notes to Consolidated Financial Statements

Note 1. Nature of Business

Axcelis Technologies, Inc. (“Axcelis” “We” or the “Company”) was incorporated in Delaware in 1995, and is a worldwide producer of ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe and Asia. In addition to equipment, we provide extensive aftermarket lifecycle products and services, including spare parts, equipment upgrades, maintenance services and customer training.

Note 2. Summary of Significant Accounting Policies

The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the footnotes.

(a) Basis of Presentation

The accompanying consolidated financial statements include the consolidated accounts of the Company and its wholly-owned, controlled subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Events occurring subsequent to December 31, 2025 have been evaluated for potential recognition or disclosure in the consolidated financial statements.

(b) Use of Estimates

The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, the realizable value of accounts receivable and inventories, warranty reserves, valuing stock-based compensation instruments and reserves relating to tax assets and liabilities. Actual amounts could differ from these estimates. Changes in estimates are recorded in the period in which they become known.

(c) Foreign Currency

The functional currency for substantially all operations outside the United States is the local currency. Financial statements for these operations are translated into United States dollars at year-end rates as to assets and liabilities and average exchange rates during the year as to revenue and expenses. The resulting translation adjustments are recorded in stockholders’ equity as an element of accumulated other comprehensive income (loss). Foreign currency transaction gains and losses are included in other income (expense) in the Consolidated Statements of Operations.

For the years ended December 31, 2025, 2024, and 2023 we had foreign exchange gains of $4.5 million and foreign exchange losses of $9.1 million, and $0.5 million, respectively.

(d) Derivative Instruments

We are exposed to certain risks relating to our ongoing business operations, including market risks relating to fluctuations in foreign currency exchange rates. We have entered into forward exchange contracts in order to mitigate risks associated with fluctuations in exchange rates on forecasted transactions denominated in foreign currencies and to minimize the impact of foreign currency fluctuations on our earnings and cash flows. These contracts have month-to-month settlement dates. As of December 31, 2025, we had open contracts with a notional value of $162.0 million. We measure these instruments at fair value and recognize assets or liabilities associated with the fair value on these open contracts on the Consolidated Balance Sheets at the end of each reporting period. At December 31, 2025, the recognized unrealized gain

on these forward exchange contracts was approximately $0.4 million. Unrealized gains and losses are shown in our cash flows from operating activities within our Consolidated Statement of Cash Flows. We have not designated these forward exchange contracts as hedging instruments and we record changes in the fair values at each measurement date in Other, net on the Consolidated Statements of Operations. For the years ended December 31, 2025 and 2024, we recorded $2.1 million of losses and $9.1 million of gains on forward currency exchange contracts, respectively.

We do not offset fair value amounts of derivative instruments. We do not use derivative instruments for speculative purposes.

(e) Cash, Cash Equivalents and Short-term Investments

Cash and cash equivalents consist of cash on hand and highly liquid investments with original maturities of 90 days or less. Cash equivalents consist primarily of money market funds, U.S. Government and Agency Securities and deposit accounts. Cash equivalents are carried on the balance sheet at fair market value. Short-term investments are highly liquid investments with original maturities of greater than 90 days but less than one year from date of purchase. Beginning as of March 31, 2025, our short-term investments are classified as available-for-sale as a result of the below noted sale of securities. In prior periods, our short-term investments were classified as held-to-maturity. We evaluate if any declines in fair value below amortized cost are caused by expected credit losses, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Any unrealized gains and losses are included in accumulated other comprehensive loss in the Consolidated Statement of Stockholders’ Equity. Income related to these securities is recorded in interest income in the Consolidated Statements of Operations. As of December 31, 2025, the amortized cost and fair value of the available-for-sale short-term investments was $228.7 million and $228.8 million, respectively. As of December 31, 2025, we hadno allowances for credit loss on our investments.

In February 2025, we sold securities classified as held-to-maturity with a total net carrying value of $199.5 million. The majority of the proceeds were reinvested back into short-term investments during the three months ended March 31, 2025. Due to this sale, the remaining held-to-maturity securities were reclassified as available-for-sale, resulting in a remeasurement increase in short-term investments for balance sheet presentation purposes with a corresponding adjustment to accumulated other comprehensive loss of $81.0 thousand as of March 31, 2025.

**(f)**Long-term Investments

Long-term investments consist of U.S. government and agency securities with original maturities greater than one year from the date of purchase and are classified as available-for-sale. We classify our long-term investments as non-current based on the security’s contractual maturity. We evaluate if any declines in fair value below amortized cost are caused by expected credit losses, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Any unrealized gains and losses are included in accumulated other comprehensive loss in the Consolidated Statement of Stockholders’ Equity. Income related to these securities is recorded in interest income in the Consolidated Statements of Operations. As of December 31, 2025, the amortized cost and fair value of the long-term investments was $182.1 million and $182.4 million, respectively. As of December 31, 2025, we hadno allowances for credit loss on our investments.

(g) Inventories

Inventories are carried at the lower of cost or net realizable value, determined using the first-in, first-out (“FIFO”) method. We periodically review our inventories and make provisions as necessary for estimated obsolescence or damaged goods to ensure values approximate lower of cost or net realizable value. The amount of such markdowns is equal to the difference between cost of inventory and the estimated market value based upon assumptions about future demands, selling prices, and market conditions.

We record a provision for estimated excess inventory. The provision is determined using management’s assumptions of materials usage, based on estimates of demand, market conditions, and the size and utilization of our installed base. If actual market conditions become less favorable than those projected by management, additional inventory write-downs may be required.

(h) Property, Plant and Equipment and Leased Assets

Property, plant and equipment are stated at cost, less accumulated depreciation and amortization.

On January 30, 2015, we sold our corporate headquarters facility. As part of this sale, we also entered into a 22-year lease agreement. We accounted for the sale leaseback transaction as a financing arrangement for financial reporting purposes. We retained the historical costs of the property and the related accumulated depreciation on our financial books within property, plant and equipment and will continue to depreciate the property for financial reporting purposes over the lesser of its remaining useful life or its initial lease term of 22 years.

Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets as follows:

​​​​​​
Asset Classification​ ​ ​Estimated Useful Life
Land, buildings and equipment (under lease)​Lesser of the lease term or estimated useful life of the asset​​
Machinery and equipment​3 to 10 years​​

Repairs and maintenance costs are expensed as incurred. Expenditures greater than $2.5 thousand for renewals and betterments are capitalized and depreciated over their useful lives.

(i) Impairment of Long-Lived Assets

We record impairment losses on long-lived assets when events and circumstances indicate that these assets might not be recoverable. Recoverability is assessed by a comparison of the assets’ carrying amount to their expected future undiscounted net cash flows. If such assets are considered to be impaired, the impairment is measured based on the amount by which the carrying value exceeds its fair value.

We did not have any indicators of impairment during the period ending December 31, 2025. We didnot record an impairment charge in the years ended December 31, 2025, 2024, or 2023.

Actual performance could be materially different from our current forecasts, which could impact estimates of undiscounted cash flows and may result in the impairment of the carrying amount of the long-lived assets in the future. This could be caused by strategic decisions made in response to economic and competitive conditions, the impact of the economic environment on our customer base, or a material adverse change in our relationships with significant customers.

** (j) Concentration of Risk and Off-Balance Sheet Risk**

Financial instruments that potentially subject us to concentrations of credit risk are principally cash equivalents, short-term investments, long-term investments and accounts receivable. Our cash equivalents, short-term investments and long-term investments are principally maintained in investment grade money-market funds, U.S. Government and Agency Securities and deposit accounts.

Other than our currency exchange contracts, we have no significant off-balance sheet risk relating to option contracts or other hedging arrangements.

Our exposure to market risk for changes in interest rates relates primarily to cash equivalents, short-term and long-term investments. The primary objective of our investment activities is to preserve principal without significantly increasing risk. This is accomplished by investing in marketable investment grade securities. We do not use derivative financial instruments to manage our investment portfolio and do not expect operating results or cash flows to be affected to any significant degree by any change in market interest rates.

We perform ongoing credit evaluations of our customers’ financial condition and generally require no collateral to secure accounts receivable. For selected overseas sales, we require customers to obtain letters of credit before product is

shipped. We maintain an allowance for doubtful accounts based on our assessment of the collectability of accounts receivable. We review the allowance for doubtful accounts quarterly. We do not have any off-balance sheet credit exposure related to our customers.

Our customers consist of semiconductor chip manufacturers located throughout the world and net sales to ourten largest customers accounted for 55.2%,45.9% and 51.7% of revenue in 2025, 2024 and 2023, respectively.

For the year ended December 31, 2025, we hadone customer representing 11.0% of total revenue. For the years ended December 31, 2024 and December 31, 2023, we hadno customers representing 10% or greater of total revenue.

As of December 31, 2025, we hadthree customers account for 14.7%,13.5% and 10.3% of consolidated accounts receivable, respectively. As of December 31, 2024, we hadone customer account for 10.0% of consolidated accounts receivable.

Some of the components and sub-assemblies included in our products are obtained either from a sole source or a limited group of suppliers. Disruption to our supply source, resulting either from economic conditions or other factors, could affect our ability to deliver products to our customers.

(k) Revenue Recognition

We recognize revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606,Revenue from Contracts with Customersor (“ASC 606”). Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration we expect to receive in exchange for those goods or services. We measure revenue based on the consideration specified in the customer arrangement, and revenue is recognized when the performance obligations in the customer arrangement are satisfied. A performance obligation is a promise in a contract to transfer a distinct product or service to the customer. The transaction price of a contract is allocated to each distinct performance obligation based upon the relative standalone selling price for each performance obligation and recognized as revenue when, or as, the customer receives the benefit of the performance obligation. To account for and measure revenue, we apply the following five steps:

1)Identify the contract with the customer

A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

2)Identify the performance obligations in the contract

Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, we must apply judgment to determine whether promised goods and services are capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.

Systems sales consist of multiple performance obligations, including the system itself and obligations that are not delivered simultaneously with the system. These undelivered obligations might include a combination of installation services, extended warranty and support and spare parts, all of which are generally covered by a single sales price.

The Aftermarket business includes both products and services type arrangements. Performance obligations in these contracts consist of used tools, spare parts, equipment upgrades, maintenance services and customer training.

Customers who purchase new systems are provided an assurance-type warranty forone year after acceptance of the tool. For aftermarket transactions, we provide customers an assurance-type warranty for 90 days. Customers can choose to purchase extended warranty terms with enhanced support similar to a service-type warranty ranging fromone tothree years. In accordance with ASC 606, assurance-type warranties are not considered a performance obligation, whereas service-type warranties are.

3)Determine the transaction price

The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. In applying this guidance, Companies must also consider whether any significant financing components exist.

The transaction price for all transactions is based on the price reflected in the individual customer’s purchase order. Variable consideration has not been identified as a significant component of the transaction price for any of our transactions.

For those transactions where all performance obligations will be satisfied within one year or less, we apply the practical expedient outlined in ASC 606-10-32-18. This practical expedient allows us not to adjust promised consideration for the effects of a significant financing component if we expect at contract inception that the period between when we transfer the promised good or service to a customer and when the customer pays for that good or service will be one year or less. For those transactions that are expected to be completed after one year, we have assessed that there are no significant financing components because any difference between the promised consideration and the cash selling price of the good or service is for reasons other than the provision of financing.

4)Allocate the transaction price to performance obligations in the contract

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation.

Where required, we determine standalone selling price (“SSP”) for each obligation based on consideration of both market and Company specific factors, including the selling price and profit margin for similar products, the cost to produce, and the anticipated margin.

For those contracts that contain multiple performance obligations (primarily systems sales, as well as some aftermarket contracts requiring both time and material inputs), we must determine the SSP. We use a cost plus margin approach in determining the SSP for any materials related performance obligations (such as upgrades, spare parts, systems). To determine the SSP for labor related performance obligations (such as the labor component of installation), we use directly observable inputs based on the standalone sale prices for these services.

5)Recognize revenue when or as we have satisfied a performance obligation

We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either 1) the customer simultaneously receives and consumes the benefits provided by the entity’s performance, 2) the entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or 3) the entity’s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related

performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets or settle liabilities, and holding or selling the asset. For over time recognition, ASC 606 requires us to select a single revenue recognition method for the performance obligation that faithfully depicts our performance in transferring control of the goods and services. The guidance allows entities to choose between two methods to measure progress toward complete satisfaction of a performance obligation:

Output methods - recognize revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract (e.g., surveys of performance completed to date, appraisals of results achieved, milestones reached, time elapsed, and units produced or units delivered); and

Input methods - recognize revenue on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation.

We have the right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date (i.e., certain aftermarket contracts), as such we have elected a practical expedient to recognize revenue in the amount to which the entity has a right to invoice for such services.

Product related revenues (whether for systems or aftermarket business) are recognized at a point in time, when they are shipped or delivered, depending on shipping terms.

For installation services, revenue is recognized at a point in time, once the installation of the tool is complete. The nature of the installation services is such that the customer does not simultaneously receive and consume the benefits provided by the entity’s performance, nor does performance of installation services create or enhance an asset that the customer controls. Installation services do not create an asset with an alternative use to the entity, and the entity does not have an enforceable right to payment for performance completed to date.

Contract liabilities are reflected as deferred revenue on the consolidated balance sheet. Contract liabilities relate to payments invoiced or received in advance of completion of performance obligations under a contract. Contract liabilities are recognized as revenue upon the fulfillment of performance obligations.

Service-type warranties for any product are recognized over time, as these represent a stand ready obligation to service the product during the warranty period. Progress in the satisfaction of these performance obligations is measured using an input method of time elapsed.

Maintenance and service contracts are recognized over time. Progress in the satisfaction of these performance obligations is measured using an input method of either time elapsed in the case of fixed period contracts, or labor hours expended, in the case of project-based contracts.

(l) Recognizing Assets related to Recoverable Customer Contract Costs

We recognize an asset related to incremental costs incurred by us to obtain a contract with a customer if we expect to recover those costs. We will recognize an asset from costs incurred to fulfill a contract only if such costs relate directly to a contract with an entity that we can specifically identify, the costs incurred will generate or enhance resources that will be used in satisfying performance obligations in the future, and the costs are expected to be recovered. Any assets recognized related to costs to obtain or fulfill a contract are amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates.

In substantially all of our business transactions, we incur incremental costs to obtain contracts with customers, in the form of sales commissions. We maintain a commission program which awards our employees for System sales, aftermarket activity and other individual goals. Under ASC 606, an asset is amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. However, ASC 606 provides

a practical expedient to allow for the recognition of commission expense when incurred if the amortization period of the asset that the entity otherwise would have recognized is one year or less. Based on the nature of our commission agreements, all commissions are expensed as incurred based upon the expectation that the amortization period would be one year or less.

(m) Shipping and Handling Costs

Shipping and handling costs are included in cost of revenue.

(n) Stock-Based Compensation

We generally recognize compensation expense for all stock-based payments to employees and directors, including grants of stock options and restricted stock units, based on the grant-date fair value of those stock-based payments. For stock option awards, we use the Black-Scholes option pricing model, adjusted for expected forfeitures. Other valuation models may be utilized in the limited circumstances where awards with market-based vesting considerations, such as the price of our common stock, or performance-based awards, are granted. Stock-based compensation expense is recognized ratably over the requisite service period. For each stock option or restricted stock unit grant with vesting based on a combination of time, market or performance conditions, where vesting will occur if either condition is met, the related compensation costs are recognized over the shorter of the explicit service period or the derived service period.

See Note 13 for additional information relating to stock-based compensation.

(o) Income Taxes

We record income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax basis, and operating loss and tax credit carryforwards.

We establish a valuation allowance if the likelihood of realization of the deferred tax assets is reduced based on an evaluation of objective verifiable evidence. Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against those net deferred tax assets. We evaluate the weight of all available evidence to determine whether it is more likely than not that some portion or all of the net deferred income tax assets will not be realized.

Income taxes include the largest amount of tax benefit for an uncertain tax position that is more likely than not to be sustained upon audit based on the technical merits of the tax position. Settlements with tax authorities, the expiration of statutes of limitations for particular tax positions, or obtaining new information on particular tax positions may cause a change to the effective tax rate. We recognize accrued interest related to unrecognized tax benefits as interest expense and penalties within operating expense in the consolidated statements of operations.

See Note 18 for additional information relating to income taxes.

(p) Computation of Net Income per Share

Basic earnings per share is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of shares of common stock outstanding (the denominator) for the period. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive shares of common stock had been issued, calculated using the treasury stock method.

The components of net income per share are as follows:

​​​​​​​​​​​
​ · ​ · ​ · ​
​ · ​ · Year ended December 31, · ​
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · 2023
​ · ​ · (in thousands, except per share data)
Net income available to common stockholders​$120,238​$200,992​$246,263​
Weighted average shares of common stock outstanding used in computing basic income per share​31,574​32,552​32,758​
Incremental RSUs​94​152​407​
Weighted average shares of common stock used in computing diluted net income per share​31,668​32,704​​33,165​
Net income per share​​​​​​​​​​
Basic​$3.81​$6.17​$7.52​
Diluted​$3.80​$6.15​$7.43​

Diluted weighted average shares of common stock outstanding does not include restricted stock units outstanding to purchase 221,204,122,294 and 6,025 common equivalent shares for the periods ended December 31, 2025, 2024 and 2023, respectively, as their effect would have been anti-dilutive.

(q) Accumulated Other Comprehensive Loss

The following table presents the changes in accumulated other comprehensive loss, by component, for the year ended December 31, 2025:

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ ​ ​ · ​ · ​ · ​ · ​ · ​ · ​ ​ ​ · Unrealized gains on · ​ ​ ​ · ​ · ​
​ · ​ · Foreign · ​ ​ ​ · Defined benefit · ​ · available-for-sale · ​ · ​ · ​ · ​
​ · ​ · currency · ​ · pension plan · ​ · investments · ​ · Total
​ · ​ · (in thousands)
Balance at December 31, 2024​$(6,253)​$39​$—​$(6,214)​
Other comprehensive income and reclassifications​3,596​(20)​436​4,012​
Balance at December 31, 2025​$(2,657)​$19​$436​$(2,202)​

(r) Recent Accounting Guidance

In December 2023 the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2023-09,Income Taxes (Topic 740): Improvements to Income Tax Disclosures("ASU 2023-09")*.*We adopted ASU 2023-09 within this Annual Report on Form 10-K and we applied the update retrospectively for all prior periods presented in the consolidated financial statements. See Note 18 for related disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 addresses investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information.

In November 2024 the FASB issued Accounting Standards Update 2024-03,Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 is intended to enhance the disclosures for expenses for all public entities in accordance with ASC Topic 220,Income Statement-Reporting Comprehensive Income. ASU 2024-03 addresses investor requests for more detailed information about expenses, specifically cost of sales and selling, general, and administrative expenses (“SG&A”). ASU 2024-03 requires a public entity to disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and (e) depreciation, depletion, and amortization recognized as part of oil- and gas-producing activities (or other amounts of depletion expense) included in each relevant expense caption presented on the face of the income statement as well as a qualitative description of the amounts remaining in the relevant expense captions that are not separately disaggregated quantitatively. ASU 2024-03 also requires a public entity to disclose the total amount of selling expenses and the entity’s definition of selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. A public entity should apply ASU 2024-03 either prospectively to

financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2024-03 on its future consolidated financial statements and related disclosures.

In September 2025, the FASB issued Accounting Standards Update 2025-06ASU No. 2025-06, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software(“ASU 2025-06”). ASU 2025-06 requires companies to start capitalizing eligible software costs when management has authorized and committed to funding the software project, and it is probable that the project will be completed and the software will be used to perform the function intended. The guidance is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted and may be applied using a prospective, retrospective or modified transition approach. The Company is currently evaluating the impact of ASU 2025-06 on its future consolidated financial statements and related disclosures.

In September 2025, the FASB issuedASU No. 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606) – Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract(“ASU 2025-07”). ASU 2025-07 applies to all entities that enter into non-exchange-traded contracts with underlying content based on operations or activities specific to one of the parties to the contract. The new guidance excludes from derivative accounting non-exchange-traded contracts with underlying content based on operations or activities specific to one of the parties to the contract. ASU 2025-07 is effective for annual reporting periods beginning after December 15, 2026, and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2025-07 on its future consolidated financial statements and related disclosures.

In December 2025, the FASB issued*ASU No. 2025-11, Interim Reporting (Topic 270)** –*Narrow-Scope Improvements(“ASU 2025-11”). ASU 2025-11 applies to all entities that provide interim financial statements and notes in accordance with generally accepted accounting principles. The new guidance improves the navigability of the required interim disclosures, clarifies when that guidance is applicable and provides additional guidance on what disclosures should be provided in interim reporting periods. ASU 2025-11 also adds a principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim and annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2025-11 on its future consolidated financial statements and related disclosures.

Note 3. Revenue

We design, manufacture and service ion implantation and other processing equipment used in the fabrication of semiconductor chips and sell our products to leading semiconductor chip manufacturers worldwide. We offer a complete line of high energy, high current and medium current implanters for all application requirements. In addition, we provide extensive aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance service and customer training. Our revenue recognition policies are set forth in Section (k) of Note 2, Summary of Significant Accounting Policies.

(a)Alternative Operational Revenue Categories used by Management

To reflect the organization of our business operations, management reviews revenue in two categories: revenue from sales of new systems and revenue arising from the sale of used systems, parts and labor to customers who own systems, which we refer to as Customer Solutions & Innovation (“CS&I”) or “aftermarket.”

Below are the revenues by categories used by management for the periods covered in this report:

​​​​​​​​​​
​ · ​ · Year ended
​ · ​ · December 31,
​ · ​ · 2025 · ​ · 2024 · ​ · 2023
​​​​​​​​​​
Systems​$571,019​$782,559​$883,604
Aftermarket​​268,029​​235,306​​247,000
Total Revenue​$839,048​$1,017,865​$1,130,604
(b)Economic Factors Affecting our Revenue: Geographic Breakdown of Revenue

Global economic conditions have a direct impact on our revenue. We are substantially dependent on sales of our products and services to customers outside of the United States. Adverse economic conditions, political instability, potential adverse tax consequences, regulatory changes and volatility in currency exchange rates pose a risk that our customers may reduce, postpone or cancel spending for our products and services, which would impact our revenue.

Revenue by geographic markets is determined based upon the location to which our products are shipped and where our services are performed. Revenue in our principal geographic markets is as follows:

​​​​​​​​​​
​ · ​ · Year ended
​ · ​ · December 31,
​ · ​ · 2025 · ​ · 2024 · ​ · 2023
​​​​​​​​​​
North America​$137,078​$144,066​$174,810
Asia Pacific​​610,211​​781,039​​811,308
Europe​​91,759​​92,760​​144,486
Total Revenue​$839,048​$1,017,865​$1,130,604
(c)Recognition of Deferred Revenue from Contract Liabilities

Contract liabilities are as follows:

​​​​​​​​​​
​ · ​ · Year ended
​ · ​ ​ · December 31,
​ · ​ · 2025 · ​ · 2024 · ​ · 2023
​​​​​​​​​​
Balance, beginning of the period​$138,174​$210,885​$154,777
Deferral of revenue​​43,945​​65,708​​185,688
Other adjustments *​​(2,803)​​(4,716)​​—
Recognition of deferred revenue​​(70,377)​​(133,703)​​(129,580)
Balance, end of the period​$108,939​$138,174​$210,885
  • Adjustment to contracts with customers are assessed to determine if amounts paid by customers represent deferred revenue or liabilities payable to customers and such amounts are accordingly reclassified pursuant to our revenue recognition policy and ASC 606.

Contract liabilities are reflected as deferred revenue on the consolidated balance sheet. Contract liabilities relate to payments received or amounts invoiced in advance of completion of performance obligations under a contract. Contract liabilities are recognized as revenue upon the fulfillment of performance obligations.

As of December 31, 2025, we had deferred revenue of $108.9 million. This represents the portion of the transaction price for contracts with customers allocated to the performance obligations that remain unsatisfied or partially unsatisfied. Short-term deferred revenue of$65.5 million as of December 31, 2025 represents performance obligations that are expected to be satisfied within the next 12 months. This amount relates primarily to prepayments made prior to system

delivery as well as to installation and non-standard warranty performance obligations for system sales. Long-term deferred revenue of $43.4 million as of December 31, 2025 relates to prepayments made prior to system delivery as well as to extended warranty performance obligations that we expect to be completed in excess of the next 12 months but within the next 24 months.

The majority of our system transactions have either (1) payment terms that are 90% due upon shipment of the system and 10% due upon acceptance or (2) a pre-shipment deposit ranging from 20% to 60%, with the remainder due upon shipment, less 10% due at acceptance. Aftermarket transaction payment terms are such that payment is due either within 30 or 60 days of service provided or parts delivered.

Note 4. Cash, cash equivalents and restricted cash

​​​​​​​
​ · December 31, · ​ · December 31, · ​
​ · 2025 · ​ · ​ · 2024 · ​
​ · (in thousands) · ​
Cash and cash equivalents$145,451​$123,512​
Long-term restricted cash​10,627​​7,552​
Total cash, cash equivalents and restricted cash$156,078​$131,064​

As of December 31, 2025, we had $10.6 million in restricted cash which relates to a $5.9 million cash collateral relating to our lease for our headquarters in Beverly, Massachusetts, a $3.9 million letter of credit for customs purposes, a $0.7 million letter of credit relating to workers’ compensation insurance and a $0.1 million deposit relating to customs activity.

Note 5. Accounts Receivable and Allowance for Credit Losses

All trade receivables are reported on the Consolidated Balance Sheets at their amortized cost adjusted for any write-offs and net of allowances for credit losses.

Axcelis maintains an allowance for credit losses, which represents an estimate of expected losses over the remaining contractual life of its receivables considering current market conditions and estimates for supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing assessments and evaluations of collectability, historical loss experience, and future expectations in estimating credit losses in its receivable portfolio. Axcelis uses historical loss experience rates and applies them to a related aging analysis while also considering customer and/or economic risk where appropriate. Determination of the proper amount of allowances requires management to exercise judgment about the timing, frequency and severity of credit losses that could materially affect the provision for credit losses and, as a result, net earnings. The allowance takes into consideration numerous quantitative and qualitative factors that include receivable type, historical loss experience, delinquency trends, collection experience, current economic conditions, estimates for supportable forecasts, when appropriate, and credit risk characteristics.

Axcelis evaluates the credit risk of the customer when extending credit based on a combination of various financial and qualitative factors that may affect its customers’ ability to pay. These factors may include the customer’s financial condition, past payment experience, and credit ratings from credit bureaus, as well as the value of the underlying collateral.

Management performs detailed reviews of its receivables on a quarterly basis to assess the adequacy of the allowances and to determine if any impairment has occurred. Amounts determined to be uncollectable are charged directly against the allowance, while amounts recovered on previously written-off accounts increase the allowance. Changes to the allowance for credit losses are maintained through adjustments to the provision for credit losses, which are charged to current period earnings.

The following table shows changes of the allowances for credit losses related to trade receivables for the twelve months ended December 31, 2025 and 2024, respectively:

​​​​​​​
​ · ​ · Year ended
​ · ​ · December 31,
​ · ​ · 2025 · ​ · 2024
​ · ​ · (in thousands)
Balance, beginning of year​$—​$460
Provision for credit losses​​—​​3,446
Charge-offs​​—​​(3,446)
Recoveries​​—​​(460)
Balance, end of year​$—​$—

The components of accounts receivable are as follows:

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024
​ · ​ · (in thousands)
Trade receivables​$168,479​$203,149​
Allowance for doubtful accounts​—​—​
Trade receivables, net​$168,479​$203,149​

Note 6. Inventories, net

The components of inventories are as follows:

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​​December 31,​December 31,​
​​ ​ ​2025​ ​ ​2024​ ​ ​
​ · ​ · (in thousands) · ​
Raw materials​$259,039​$227,141​
Work in process​51,761​34,490​
Finished goods (completed systems)​18,210​20,594​
Inventories, net​$329,010​$282,225​

When recorded, inventory reserves are intended to reduce the carrying value of inventories to their net realizable value. We establish inventory reserves when conditions exist that indicate inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for our products or market conditions. We regularly evaluate our ability to realize the value of inventories based on a combination of factors including the following: forecasted sales and the size and utilization of our installed base, estimated product end of life dates, estimated current and future market value and new product introductions. Purchasing and usage alternatives are also explored to mitigate inventory exposure. In 2025, we recorded an increase of $0.7 million in inventory reserves. At December 31, 2025 and 2024, inventories are stated net of inventory reserves of $6.5 million and $5.8 million, respectively.

During the years ended December 31, 2025, 2024 and 2023, we recorded charges to cost of sales of $3.9 million, $6.0 million and $5.2 million, respectively, to adjust inventories to their lower of cost or net realizable value.

We have inventory on consignment at customer locations at December 31, 2025 and 2024, of $4.7 million and $5.6 million, respectively.

Note 7. Property, Plant and Equipment, net

The components of property, plant and equipment are as follows:

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024
​ · ​ · (in thousands)
Land and buildings​$31,051​$25,813​
Machinery and equipment​49,174​45,482​
Construction in process​13,171​13,598​
Total cost​93,396​84,893​
Accumulated depreciation​(37,250)​(31,109)​
Property, plant and equipment, net​$56,146​$53,784​

Depreciation expense was $8.7 million, $7.7 million and $6.2 million for the years ended December 31, 2025, 2024 and 2023, respectively.

Note 8. Assets Manufactured for Internal Use, net

Assets manufactured for internal use, included in other assets, are depreciated using the straight-line method over their 10-20 year estimated useful life. Their components are as follows:

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024
​ · ​ · (in thousands)
Internal use assets​$88,575​$90,252​
Construction in process​1,365​964​
Total cost​89,940​91,216​
Accumulated depreciation​(50,016)​(46,045)​
Assets manufactured for internal use, net​$39,924​$45,171​

These products are used for research and development, training, and customer demonstration purposes.

Depreciation expense was $7.7 million, $6.8 million and $5.6 million for the years ended December 31, 2025, 2024 and 2023, respectively.

Note 9. Leases

We have operating leases for manufacturing, office space, warehouse space, computer and office equipment and vehicles used in our business operations. We have a finance lease in relation to the 2015 sale-leaseback of our corporate headquarters in Beverly, Massachusetts. We review all agreements to determine if the agreement contains a lease component. An agreement contains a lease component if it provides the use of a specific physical space or a specific physical item.

We recognize operating lease obligations under Accounting Standards Codification -Leases (“Topic 842”). The guidance in Topic 842 requires recognition of lease assets and related liabilities on a discounted basis using the explicit or implicit discount rate stated within the agreement. We recognize a corresponding right-of-use asset, which is initially determined based upon the net present value of the associated liability and is adjusted for deferred costs and possible impairment, if any. For those lease agreements that do not indicate the applicable discount rate, we use our incremental borrowing rate. The value of the right-of-use asset is initially determined based on the net present value of the associated liability, and is adjusted for deferred costs and possible impairments, if any. We have made the following policy elections: (i) operating leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet; (ii) we recognize lease expense for operating leases on a straight-line basis over the lease term; and (iii) we account for lease components and non-lease components that are fixed payments as one component. Some of our operating leases include one or more options to renew, with renewal terms that can extend the respective lease term 1 to 3 years. The exercise of lease renewal options is at our sole discretion. For lease extensions that are reasonably certain to occur, we have included

the renewal periods in our calculation of the net present value of the lease obligation and related right-of-use asset. Certain leases also include options to purchase the leased property. The depreciable life of certain assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. The amounts of operating and finance lease right-of-use assets and related lease obligations recorded within our consolidated balance sheets are as follows:

​​​​​​​​​​​
​ · ​ · ​ · December 31, · ​ · December 31, · ​ · ​ · ​
Leases · Classification · ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · ​
Assets · ​ · ​ · (in thousands) · ​ · ​
Operating leasesOperating lease assets​$28,927​$29,621​​​
Finance leaseFinance lease assets*​14,154​15,346​​​
Total leased assets​​$43,081​$44,967​​​
Liabilities​​​​​​​​​​
Current​​​​​​​​​​
OperatingOther current liabilities​$4,859​$4,470​​​
FinanceCurrent portion of finance lease obligation​​1,575​​1,345​​​
Non-current​​​​​​​​​​
OperatingOther long-term liabilities​​24,613​​25,321​​​
FinanceFinance lease obligation​40,754​42,329​​​
Total lease liabilities​​$71,801​$73,465​​​
​​​​​​​​​​​
*Finance lease assets are recorded net of accumulated depreciation of $47.7 million and include $0.5 million of prepaid financing costs as of December 31, 2025. Finance lease assets are recorded net of accumulated depreciation of $47.4 million and include $0.5 million of prepaid financing costs as of December 31, 2024.​​​

Our operating lease office locations support local selling and servicing functions. Our Axcelis Asia Operations Center facility in South Korea is used to manufacture our products for Asia-based customers. We lease a logistics and flex manufacturing center in Beverly, Massachusetts to support our principal product manufacturing operations at our corporate headquarters. Lease expense, depreciation expense relating to finance leased assets and interest expense relating to our finance lease obligation recognized within our consolidated statement of operations for the twelve-month periods ended

December 31, 2025, 2024 and 2023 are as follows:

​​​​​​​​​​​​​
​ · ​ · ​ · Year ended · ​
​ · ​ · ​ · December 31, · ​ · ​
Lease cost · Classification · ​ ​ ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · 2023 · ​
Operating lease cost · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
Product / services*Cost of revenue​$6,471​$6,898​$7,297​​
Research and developmentOperating expenses​636​622​587​​
Sales and marketing*Operating expenses​1,833​1,817​1,674​​
General and administrative*Operating expenses​1,095​991​1,111​​
Total operating lease cost​​$10,035​$10,328​$10,669​​
Finance lease cost​​​​​​​​​​​​
Depreciation of leased assetsCost of revenue, Research and development, Sales and marketing and General and administrative​$1,193​$1,285​$1,310​​
Interest on lease liabilitiesInterest expense​4,573​4,727​4,874​​
Total finance lease cost​​$5,766​$6,012​$6,184​​
​​​​​​​​​​​​​
Total lease cost​​$15,801​$16,340​$16,853​​
​​​​​​​​​​​​​
* Product / services, sales and marketing and general and administrative expense also includes short-term lease and variable lease costs of approximately $1.8 million, $2.1 million and $2.1 million for the years ended December 31, 2025, 2024 and 2023, respectively.​​

Our corporate headquarters, shown below under finance leases, has an original lease term of 22 years. All other locations are treated as operating leases, with lease terms ranging from 1 to 16 years. The tables below reflect the minimum cash outflow regarding our current lease obligations as well as the weighted-average remaining lease term and weighted-average discount rates used in our calculation of our lease obligations and right-of-use assets:

​​​​​​​​​​​
​ · ​ · Finance · ​ · Operating · ​ ​ ​ · Total
Maturity of Lease Liabilities · ​ · Leases · ​ · Leases · ​ · Leases · ​
​ · ​ · (in thousands) · ​
2026​$6,008​$6,330​$12,338​
2027​6,128​4,433​10,561​
2028​6,251​3,110​9,361​
2029​6,376​2,649​9,025​
2030​​6,503​​2,654​​9,157​
Thereafter​​42,456​​20,217​​62,673​
Total lease payments​$73,722​$39,393​$113,115​
Less interest portion*​​(31,393)​​(9,921)​​(41,314)​
Finance lease and operating lease obligations​$42,329​$29,472​$71,801​
​​​​​​​​​​​
* Finance lease interest calculated using the implied interest rate; operating lease interest calculated using estimated corporate borrowing rate.​

The table above does not include options to renew lease terms that are not reasonably certain of being exercised as of December 31, 2025.

​​​​​
​ · ​ · December 31, · ​
Lease term and discount rate · ​ ​ ​ · 2025 · ​
Weighted-average remaining lease term (years):​​​​
Operating leases​​10.3​
Finance leases​11.1​
Weighted-average discount rate:​​​​
Operating leases​5.3%​
Finance leases​10.5%​
​​​​​

Our cash outflows from our operating leases include rent expense and other charges associated with these leases. These cash flows are included within the operating section of our statement of cash flows. Our cash flows from our finance lease include an interest and payment of principal component. The table below shows our cash outflows, by lease type and related section of our statement of cash flows, as well as the non-cash amount capitalized on our balance sheet in relation to our operating lease right-of-use assets:

​​​​​​​​​​​
​​​​​​​​​​​
​ · ​ · Year ended December 31, · ​
Cash paid for amounts included in the measurement of lease liabilities · ​ ​ ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · 2023 · ​
​ · ​ · (in thousands) · ​
Operating cash outflows from operating leases​$10,035​$10,328​$10,669​
Operating cash outflows from finance leases​4,573​4,727​4,874​
Financing cash outflows from finance leases​1,357​1,525​1,240​
Operating lease assets obtained in exchange for operating lease liabilities​4,640​5,324​26,890​
Finance lease assets obtained in exchange for new finance lease liabilities​—​—​—​
​​​​​​​​​​​

Note 10. Product Warranty

We generally offer aone-year warranty for all of our systems, the terms and conditions of which vary depending upon the product sold. For all systems sold, we accrue a liability for the estimated cost of standard warranty at the time of system shipment and defer the portion of systems revenue attributable to the fair value of non-standard warranty. Costs for non-standard warranty are expensed as incurred. Factors that affect our warranty liability include the number of installed units, historical and anticipated product failure rates, material usage and service labor costs. We periodically assess the adequacy of our recorded liability and adjust the amount as necessary.

The changes in our product warranty liability are as follows:

​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Year ended December 31, · ​
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · 2023
​ · ​ · (in thousands)
Balance at January 1 (beginning of year)​$15,183​$16,757​$10,487​
Warranties issued during the period​9,102​11,263​12,893​
Settlements made during the period​(11,859)​(12,160)​(10,230)​
Changes in estimate of liability for pre-existing warranties during the period​(839)​(677)​3,607​
Balance at December 31 (end of year)​$11,587​$15,183​$16,757​
​​​​​​​​​​​
Amount classified as current​$9,516​$13,022​$14,098​
Amount classified as long-term (within other long-term liabilities)​2,071​2,161​2,659​
Total warranty liability​$11,587​$15,183​$16,757​

Note 11. Financing Arrangements

On January 30, 2015, we sold our corporate headquarters facility for the sale price of $48.9 million. As part of the sale, we also entered into a 22-year lease agreement with the buyer. The sale leaseback is accounted for as a financing arrangement for financial reporting purposes and, as such, we recorded a financing obligation of $42.3 million as of December 31, 2025, $1.6 million of which is classified within current liabilities. The associated lease payments include both an interest component and payment of principal, with the underlying liability being extinguished at the end of the original lease term. As of December 31, 2025, we had a security deposit of $5.9 million related to this lease in the form of a cash collateralized letter of credit issued with UBS Bank USA, which is classified as long-term restricted cash on our balance sheet at December 31, 2025.

Note 12. Employee Benefit Plans

(a) Defined Contribution Plan

We maintain the Axcelis Long-Term Investment Plan, a defined contribution plan. Eligible employees may contribute up to 35% of their compensation on a before-tax basis subject to Internal Revenue Service (“IRS”) limitations. Highly compensated employees may contribute up to 16% of their compensation on a before-tax basis subject to IRS limitations. In 2025, 2024 and 2023, we provided an employer match of 50% of employees’ pre-tax contributions on the first 6% of eligible compensation. Total related matching contribution expense was $3.1 million, $3.4 million and $3.4 million, for 2025, 2024 and 2023, respectively.

(b) Other Compensation Plans

We operate in foreign jurisdictions that require lump sum benefits, payable based on statutory regulations, for voluntary or involuntary termination. Where required, an annual actuarial valuation of the benefit plans is obtained.

We have recorded an unfunded liability of $3.6 million and $3.1 million at December 31, 2025 and 2024, respectively, for costs associated with these compensation plans in foreign jurisdictions. The following table presents the classification of these liabilities in the Consolidated Balance Sheets:

​​​​​​​​
​ · ​ · Year ended
​ · ​ · December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024
​ · ​ · (in thousands)
Long-term:​​​​​​​
Other long-term liabilities​​3,623​​3,117​
Total liabilities​$3,623​$3,117​

The expense recorded in connection with these plans was $1.7 million for each of the years ended December 31, 2025, 2024 and 2023.

Note 13. Stock Award Plans and Stock-Based Compensation

(a) Equity Incentive Plans

We maintain the Axcelis Technologies, Inc. 2012 Equity Incentive Plan (the “2012 Equity Plan” or the “Plan”), which became effective on May 2, 2012.

The 2012 Equity Plan, as amended, reserves 12.5 million shares of common stock, $0.001 par value, for grant and permits the issuance of options, stock appreciation rights, restricted stock, restricted stock units, stock equivalents and awards of shares of common stock that are not subject to restrictions or forfeiture to selected employees, directors, and consultants of the Company. The total number of shares reserved for issuance under the Plan is the sum of 10.76 million shares approved by the shareholders, and 1.78 million shares added in accordance with the terms of the Plan as a result of

the expiration or forfeiture of awards granted under our prior equity plan. Shares that are not issued under an award (because such award expires, is terminated unexercised or is forfeited) revert back to the Plan.

The term of stock options granted under the Plan is specified in the award agreements. Unless a lesser term is otherwise specified by the Compensation Committee of the Company’s Board of Directors, option awards under the 2012 Equity Plan will expire seven years from the date of grant. Under the terms of the Plan, the exercise price of a stock option may not be less than the fair market value of a share of the Company’s common stock on the date of grant. Under the 2012 Equity Plan, fair market value is defined as the last reported sale price of a share of the Company’s common stock on a national securities exchange as of any applicable date, as long as the Company’s shares are traded on such exchange.

Stock options granted to employees generally vest over a period offour years, while stock options granted to non-employee members of the Company’s Board of Directors generally vest over a period ofsix months and, once vested, are not affected by the director’s termination of service to the Company. In limited circumstances, the Company may grant stock option awards with market-based vesting conditions, such as the Company’s common stock price, or other performance conditions. Termination of service by an employee will cause options to cease vesting as of the date of termination, and in most cases, employees will have 90 days after termination to exercise options that were vested as of the termination of employment. In general, retiring employees will haveone year after termination of employment to exercise vested options. The Company settles stock option exercises with newly issued shares of common stock.

Restricted stock units granted to employees during 2025 had both service-based vesting provisions and performance-based vesting provisions. Restricted stock units granted to employees generally vest over a service period offour years, while restricted stock units granted to non-employee members of the Company’s Board of Directors in 2025 vest over a service period ofone year. We have granted restricted stock units to executive officers and other senior employees with performance vesting conditions, which may be subject to further service-based vesting terms. Unvested restricted stock unit awards expire upon termination of service to the Company. We settle restricted stock units upon vesting with newly issued shares of common stock.

As of December 31, 2025, there were 2.7 million shares available for grant under the 2012 Equity Plan.

As of December 31, 2025, there wereno options outstanding and 0.7 million unvested restricted stock units outstanding under the 2012 Stock Plan.

(b) Employee Stock Purchase Plan

The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) provides our employees an opportunity to purchase common stock of the Company at less than market prices. Purchases are made through payroll deductions of up to 10% of the employee’s salary as elected by the participant, subject to certain caps set forth in the 2020 ESPP. Employees may purchase the Company’s common stock at 85% of its market price on the day the stock is purchased.

The 2020 ESPP is considered compensatory and as such, compensation expense has been recognized based on the benefit of the discounted stock price, amortized to compensation expense over each offering period ofsix months. Compensation expense relating to the 2020 ESPP was approximately $0.4 million for each of the years ended December 31, 2025, 2024 and 2023.

As of December 31, 2025, there were approximately 0.8 million shares reserved for issuance and available for purchase under the 2020 ESPP, with 18 thousand shares purchased on that date to be issued pending settlement.38 thousand shares,30 thousand shares, and 16 thousand shares were purchased under the 2020 ESPP for the year ended December 31, 2025, 2024 and 2023, respectively.

(c) Valuation of Restricted Stock Units

The fair value of the Company’s restricted stock units is calculated based upon the fair market value of the Company’s stock at the date of grant.

(d) Summary of Stock-based Compensation Expense

We use the straight-line attribution method to recognize expense for stock-based awards such that the expense associated with awards is evenly recognized throughout the period.

The amount of stock-based compensation recognized is based on the value of the portion of the awards that are ultimately expected to vest. We estimate forfeitures at the time of grant and revise them, if necessary, in subsequent periods, if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. Based on a historical analysis, a forfeiture rate of 5% per year was applied to stock-based awards, including executive officer awards, for the years ended December 31, 2025, 2024 and 2023.

For the years ended December 31, 2025, 2024 and 2023, we recognized stock-based compensation expense of $20.8 million, $21.0 million and $18.3 million, respectively. We present the expenses related to stock-based compensation in the same expense line items as cash compensation paid to our employees. For the years ended December 31, 2025, 2024 and 2023, we used restricted stock units in our annual equity compensation program.

With regard to stock-based compensation, the statement of cash flows will report a net benefit related to tax deductions in excess of recognized compensation cost or a net charge related to non-deductible compensation cost. For the year ended December 31, 2025, the net charge related to non-deductible stock compensation was $1.2 million.

(e) Restricted Stock Units and Restricted Stock

Restricted stock units represent the Company’s unfunded and unsecured promise to issue shares of the common stock at a future date, subject to the terms of the Award Agreement issued under the 2012 Equity Incentive Plan. Restricted stock unit awards granted in 2025 included time vested share awards and awards with performance vesting conditions. Restricted stock awards are issued shares of common stock that are subject to forfeiture on terms described in the Award Agreement, and may be granted under the 2012 Equity Incentive Plan. No restricted stock awards were granted, or vested, during the years ended December 31, 2025, 2024 and 2023. The fair value of a restricted stock unit and restricted stock award is charged to expense ratably over the applicable service period. The purpose of these awards is to assist in attracting and retaining highly competent employees and directors and to act as an incentive in motivating selected employees and directors to achieve long-term corporate objectives.

Changes in the Company’s non-vested restricted stock units for the year ended December 31, 2025 is as follows:

​ · ​ · ​ · ​ · ​ · ​ · ​
​​ ​ ​​​ ​ ​Weighted-Average
​​​​Grant Date Fair
​​Shares/units​Value per Share
​ · ​ · (in thousands) · ​ · ​ · ​ · ​
Outstanding at December 31, 2024465​$103.09​
Granted483​65.30​
Vested(214)​95.71​
Forfeited(30)​96.44​
Outstanding at December 31, 2025704​$79.69​

The weighted average grant-date fair value of restricted stock units granted for the years ended December 31, 2025, 2024 and 2023 was $65.30, $112.45 and $125.11, respectively. Most restricted stock units provide for net share settlement to cover the employee’s personal income tax withholding obligations on vesting of the employee’s restricted stock units. Vesting activity above reflects shares vested before net share settlement. As of December 31, 2025, there was $43.7 million of total forfeiture-adjusted unrecognized compensation cost related to non-vested restricted stock units granted under the 2012 Equity Incentive Plan. That cost is expected to be recognized over a weighted-average period of 2.6 years.

Note 14. Stockholders’ Equity

We may issue up to 75 million shares of common stock without additional shareholder approval. At December 31, 2025 and 2024, there were 30.7 million and 32.4 million outstanding shares of common stock, respectively.

Note 15. Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

(a) Fair Value Hierarchy

The accounting guidance for fair value measurement requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is as follows:

Level 1—applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2—applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3—applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

(b) Assets and Liabilities Measured at Fair Value

Our money market funds and short-term investments with maturities of 90 days or less at time of purchase are included in cash and cash equivalents in the consolidated balance sheets. Short-term investments with maturities greater than 90 days but not greater than 365 days are included in short-term investments in the consolidated balance sheets. Investments that have a maturity of greater than one year are included within long-term investments in the consolidated balance sheets.

The following table sets forth the Company’s assets which are measured at fair value by level within the fair value hierarchy.

​​​​​​​​​​​​​​
​ · ​ · December 31, 2025
​ · ​ · Fair Value Measurements
​ · ​ ​ ​ · Level 1 · ​ ​ ​ · Level 2 · ​ ​ ​ · Level 3 · ​ ​ ​ · Total
​ · ​ · (in thousands)
Assets​​​​​​​​​​​​​
Cash equivalents and other short-term investments:​​​​​​​​​​​​​
Cash equivalents (money market funds, U.S. Government Securities and Agency Investments)​$93,348​$—​$—​$93,348​
Short-term investments (U.S. Government Securities and Agency Investments)​​228,802​​—​​—​​228,802​
Mark-to-market adjustment on forward exchange contracts​​—​​435​​—​​435​
Long-term investments (U.S. Government Securities and Agency Investments)​​182,396​​—​​—​​182,396​
Total​$504,546​$435​$—​$504,981​
​​​​​​​​​​​​​​
​ · ​ · December 31, 2024
​ · ​ · Fair Value Measurements
​ · ​ ​ ​ · Level 1 · ​ ​ ​ · Level 2 · ​ ​ ​ · Level 3 · ​ ​ ​ · Total
​ · ​ · (in thousands)
Assets​​​​​​​​​​​​​
Cash equivalents and other short-term investments:​​​​​​​​​​​​​
Cash equivalents (money market funds, U.S. Government Securities and Agency Investments)​$81,320​$—​$—​$81,320​
Short-term investments (U.S. Government Securities and Agency Investments)​​448,296​​—​​—​​448,296​
Mark-to-market adjustment on forward exchange contracts​​—​​267​​—​​267​
Total​$529,616​$267​$—​$529,883​

The following table summarizes the contractual maturities of our cash equivalents and investments as of December 31, 2025:

​ · ​ · ​ · ​ · ​ · ​ · ​
​​ ​ ​Amortized Cost​ ​ ​Fair Value
​ · ​ · (in thousands)
Due within one year​$322,032​$322,150
Due after one year through two years​182,078​182,396
Total​$504,110​$504,546

(c) Other Financial Instruments

The carrying amounts reflected in the consolidated balance sheets for accounts receivable, prepaid expenses and other current and non-current assets, restricted cash, accounts payable and accrued expenses approximate fair value due to their short-term maturities.

(d) Forward Currency Exchange Contracts

We enter into forward currency exchange contracts to minimize the impact of foreign currency fluctuations on our earnings and cash flows. These contracts have month-to-month settlement dates. Any gains or losses on these contracts are reported within Other, net in our Consolidated Statement of Operations. Any open contracts at period end that have settlement dates within one month after the reported period end are marked-to-market and the valuation adjustments related to these open contracts are recorded in the current asset or current liability account. Any unrealized gain or loss on the open contracts is recognized and recorded within Other, net in our Consolidated Statement of Operations. These contracts are measured at fair value using observable market inputs such as forward currency exchange rates and our counterparties’ credit risks. Based on these inputs, the derivative instruments are classified within Level 2 of the valuation hierarchy. At December 31, 2025, the recognized unrealized gain on these forward exchange contracts was approximately $0.4 million. Based on our continued ability to trade and enter into forward contracts, we consider the markets for our fair value instruments to be active. We evaluated the credit risk associated with the counterparties to these derivative instruments and

determined that as of December 31, 2025, such credit risks have not had an adverse impact on the fair value of these instruments.

Note 16. Commitments and Contingencies

In addition to the finance and operating leases discussed in Note 9, we have purchase commitments and other contingency considerations. See Footnote 19 for contingency considerations related to the proposed merger with Veeco Instruments Inc.

(a) Purchase Commitments

We have contracts and purchase orders for inventory and other expenditures of $178.0 million at December 31, 2025, approximately $171.0 million of which are expected to occur in 2026.

(b) Litigation

We are not presently a party to any litigation that we believe might have a material adverse effect on our business operations. We are, from time to time, a party to litigation that arises in the normal course of our business operations.

(c) Indemnifications

Our system sales agreements typically include provisions under which we agree to take certain actions, provide certain remedies and defend our customers against third-party claims of intellectual property infringement under specified conditions and to indemnify customers against any damage and costs awarded in connection with such claims. We have not incurred any material costs as a result of such indemnifications and have not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.

Note 17. Business Segment and Geographic Region Information

We operate inone business segment, which is the manufacture of capital equipment for the semiconductor chip manufacturing industry. The principal market for semiconductor capital equipment is semiconductor chip manufacturers. Substantially all sales are made directly by us to our customers located in the United States, Europe and Asia Pacific.

The Company’s chief operating decision maker (“CODM”) is our chief executive officer. The CODM assesses financial performance for the company and decides how to allocate resources based on consolidated net income, such as determining the amount of resources to allocate to research and development projects, stock repurchases, or other growth opportunities. Segment asset information is provided to the CODM but it is not used to allocate resources.

The following table presents selected financial information with respect to the Company’s single operating segment for the years ended December 2025, 2024, and 2023:

​​​​​​​​​​
​ · ​ · Year ended December 31,
​ · ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · 2023
​ · ​ · (in thousands)
Revenue:​$839,048​$1,017,865​$1,130,604
Less:​​​​​​​​​
Cost of revenue​​462,200​​563,211​​639,303
Research and development​​108,958​​105,497​​96,907
Sales and marketing​​65,368​​68,046​​62,805
General and administrative​​83,207​​70,317​​65,794
Total other income​​18,934​​19,480​​12,804
Income tax provision​​18,011​​29,282​​32,336
Segment Net Income​$120,238​$200,992​$246,263
Reconciliation of profit or loss Adjustments and reconciling items​​-​​-​​-
Net income​$120,238​$200,992​$246,263

The above table includes depreciation expense and amortization expense of $17.6 million, $15.8 million and $13.1 million, for the years ended December 31, 2025, 2024, and 2023, respectively.

Our ion implantation systems product line includes high current, medium current and high energy implanters. Other legacy processing products include curing and thermal processing systems. In addition to new equipment, we provide post-sales equipment service and support, including spare parts, equipment upgrades, used equipment, maintenance services and customer training.

Revenue by product lines is as follows:

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Year ended December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · 2023
​ · ​ · (in thousands)
Ion implantation systems and services​$824,098​$1,001,045​$1,111,278​
Other systems and services​14,950​16,820​19,326​
Total revenue​$839,048​$1,017,865​$1,130,604​

Revenue and long-lived assets by geographic region, based on the physical location of the operation recording the sale or the asset, are as follows:

​​​​​​​​
​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · Long-Lived
​ · ​ · Revenue · ​ · Assets
​ · ​ · (in thousands)
2025​​​​​​​
United States​$482,641​$91,183​
Europe​49,954​263​
Asia Pacific​306,453​4,624​
​​$839,048​$96,070​
2024​​​​​​​
United States​$632,028​$94,132​
Europe​38,089​311​
Asia Pacific​347,748​4,512​
​​$1,017,865​$98,955​
2023​​​​​​​
United States​$749,288​$86,482​
Europe​45,583​382​
Asia Pacific​335,733​4,040​
​​$1,130,604​$90,904​

Long-lived assets consist of property, plant and equipment, net, and assets manufactured for internal use, net. Operations in Asia Pacific consist of manufacturing, sales and service organizations. Operations in Europe consist of sales and service organizations.

International revenue, which includes export sales from U.S. manufacturing facilities to foreign customers and sales by foreign subsidiaries and branches, was $702.0 million (83.7% of total revenue), $873.8 million (85.8% of total revenue) and $950.4 million (84.1% of total revenue) in 2025, 2024 and 2023, respectively.

Note 18. Income Taxes

Income before income taxes is as follows:

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Year ended December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · 2023
​ · ​ · (in thousands)
United States​$118,896​$222,160​$270,842​
Foreign​19,353​8,114​7,757​
Income before income taxes​$138,249​$230,274​$278,599​

Provision for income taxes is as follows:

​​​​​​​​​​​
​ · ​ · Year ended December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · 2023
​​(in thousands)
Current:​​​​​​​​​​
United States​​​​​​​​​​
Federal​$22,762​$38,963​$46,871​
State​1,122​2,026​1,985​
Foreign​4,824​3,887​3,498​
Total current​28,708​44,876​52,354​
Deferred:​​​​​​​​​​
Federal​​(10,478)​​(13,758)​​(18,526)​
State​​279​​205​​(440)​
Foreign​(498)​(2,041)​(1,052)​
Total deferred​(10,697)​(15,594)​(20,018)​
Income tax provision​$18,011​$29,282​$32,336​

Reconciliation of income taxes at the United States Federal statutory rate to the effective income tax rate of 13.0% is as follows:

​​​​​​​​​​​​​​​​​​​​
​ · ​ · Year ended December 31, · ​
​ · ​ ​ ​ · 2025 · ​ · 2024 · ​ · 2023 · ​
​ · ​ · Dollar · ​ · Percentage · ​ · Dollar · ​ · Percentage · ​ · Dollar · ​ · Percentage · ​
​ · ​ · (dollars in thousands) · ​
Adjusted Pre-Tax Book Income​$138,249​​​​$230,274​​​​$278,599​​​​
U.S. Federal Statutory Tax Rate​​29,032​21.0%​​48,358​21.0%​​58,506​21.0%​
State Income Taxes, net of federal income tax benefit*​​1,271​0.9%​​1,828​0.8%​​1,220​0.4%​
Foreign Tax Effects​​​​​​​​​​​​​​​​​​​
South Korea​​​​​​​​​​​​​​​​​​​
Withholding Taxes​​552​0.4%​​3,268​1.4%​​5,062​1.8%​
Other​​(221)​(0.2)%​​(265)​(0.1)%​​211​0.1%​
Other Jurisdictions​​512​0.3%​​378​0.2%​​533​0.2%​
Tax Credits​​​​​​​​​​​​​​​​​​​
Research and Development Credit​​(3,030)​(2.2)%​​(4,142)​(1.8)%​​(4,577)​(1.6)%​
Effect of Cross-Border Tax Laws​​​​​​​​​​​​​​​​​​​
Foreign-derived intangible income​​(12,241)​(8.9)%​​(20,439)​(8.9)%​​(24,052)​(8.6)%​
Foreign Tax Credit​​(552)​(0.4)%​​(3,268)​(1.4)%​​(5,062)​(1.8)%​
Other​740.1%​42—%​45—%
Valuation Allowances​​113​0.1%​​1,379​0.6%​​1,999​0.7%​
Nontaxable or Nondeductible Items​​​​​​​​​​​​​​​​​​​
Nondeductible Compensation​6680.5%​2,8341.2%​4,4881.6%
Share-based Compensation​​1,815​1.3%​​(2,765)​(1.2)%​​(6,718)​(2.4)%​
Other nontaxable or nondeductible Items​1090.1%​2690.1%​2150.1%
Changes in Unrecognized Tax Benefits​​242​0.2%​​761​0.3%​​1,053​0.3%​
Other Adjustments​(333)(0.2)%​1,044​0.5%​(587)​(0.2)%​
Income Tax Expense​$18,011​13.0%​$29,282​12.7%​$32,336​11.6%​
  • The states that contribute to the majority (greater than 50%) of the tax effect in this category include California, Texas, and Utah in 2025, Oregon, New York, and Maine for 2024, and Oregon, Minnesota, and Vermont for 2023.

The amounts of cash paid for income taxes (net of refunds) during the years ended December 31, 2025, 2024 and 2023 are as follows:

​​​​​​​​​​​
​ · ​ · Year ended December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024 · ​ ​ ​ · 2023
​ · ​ · (in thousands)
U.S. Federal​$7,850​$44,495​$48,900​
State​​​​​​​​​
California​​1,358​​*​​*​
Other​1,087​3,569​2,928​
Foreign​​​​​​​​​​
South Korea​​​​​​​​​​
Withholding Tax​​2,368​​3,268​​5,062​
Other​​1,586​​1,934​​891​
Other Jurisdictions​1,406​1,560​1,496​
Total Income Taxes Paid (net of refunds)​$15,655​$54,826​$59,277​

*The amount of income taxes paid during the years ended December 31, 2024 and 2023 does not meet the 5% disaggregation threshold and is included in ‘Other’.

Deferred income taxes reflect the effect of temporary differences between the carrying amounts of assets and liabilities recognized for financial reporting purposes and the amounts recognized for tax purposes. The tax effects of the temporary differences were as follows:

​​​​​​​​
​ · ​ · Year ended December 31,
​ · ​ · 2025 · ​ · 2024
​ · ​ ​ ​ · (in thousands)
Deferred tax assets: · ​ · ​
State net operating loss carryforwards​$44​$52​
Foreign net operating loss carryforwards​131​122​
Federal tax credit carryforwards​3,491​3,378​
State tax credit carryforwards​12,510​11,357​
Property, plant and equipment​3,242​4,896​
Operating lease liability​​5,095​​5,504​
Accrued compensation​​152​​313​
Inventories​​—​​552​
Stock compensation​2,089​2,399​
Warranty​2,032​2,666​
Deferred revenue​​7,523​​6,562​
Transaction Costs​​3,103​​—​
Capitalized research and development costs​​61,699​​54,673​
Other​​2,851​​—​
Gross deferred tax assets​​103,962​​92,474​
Valuation allowance​(16,001)​(14,736)​
Net deferred tax assets​​87,961​​77,738​
Deferred tax liabilities:​​​​​​​
Inventories​(641)​—​
Right-of-use asset​​(8,013)​​(8,750)​
Other​(945)​(711)​
Gross deferred tax liabilities​(9,599)​(9,461)​
Deferred taxes, net​$78,362​$68,277​

At December 31, 2025, we had a balance of $1.5 million related to deferred tax liabilities recorded within other long-term liabilities on the Consolidated Balance Sheets.

Changes in tax rates and tax laws are accounted for in the period of enactment. Our deferred tax assets and liabilities are measured at the enacted tax rate expected to apply when these temporary differences are expected to be realized or settled.

At December 31, 2025, we maintained a $16.0 million valuation allowance in the U.S. against federal and state tax credit carryforwards of the same amount. The valuation allowance was recorded due to the uncertainty of their realization based on long-term Company forecasts and the expiration dates on these attributes. This represents an increase of $1.3 million from the prior year.

At December 31, 2025, we had research and development and other tax credit carryforwards of $19.3 million. These carry forwards are fully valued and are also subject to an uncertain tax position reserve of $3.4 million. These credits can be used to reduce future federal and state income tax liabilities and expire principally between 2026 and 2040.

We consider the undistributed earnings of our foreign subsidiaries as of December 31, 2025 to be indefinitely reinvested and, accordingly, no U.S. income taxes have been provided thereon. As of December 31, 2025, there isno excess cash associated with indefinitely reinvested foreign earnings. We did not, nor do we anticipate the need to, repatriate funds to the United States to satisfy domestic liquidity needs arising in the ordinary course of business.

We and our subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. We and most foreign subsidiaries are subject to income tax examinations by tax authorities for all years dating back to 2022. We are under an IRS income tax audit for the year ended December 31, 2023. Such jurisdictions may assess

additional income tax against us. The final determination of tax audits or any administrative appeals relating thereto could be materially different from our income tax provisions and accruals. The ultimate result of any current or future audit could have a material adverse effect on our results of operations and cash flows in the period or periods for which that determination is made. Our policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. We believe that we have appropriate support for the income tax positions taken and to be taken on our tax returns and that our accruals for tax liabilities are adequate for all open years based on an assessment of many factors including past experience and interpretations of tax law applied to the facts of each matter.

At December 31, 2025, we had unrecognized tax benefits related to uncertain tax positions of $12.7 million, $9.3 million of which is recorded as a long-term liability, and the remainder of which reduced the Company’s state deferred tax assets and the offsetting valuation allowance. We recognized $0.7 million in interest and penalty expenses for the year ended December 31, 2025 relating to these uncertain tax positions. These unrecognized tax benefits, if recognized, would reduce the effective tax rate and also reverse associated accrued interest and penalty expenses included in profit before tax.

A reconciliation of the beginning and ending balance of unrecognized tax benefits are as follows:

​​​​​​​​​​​
​ · ​ ​ ​ · ​ · Year ended December 31,
​ · ​ · 2025 · ​ · 2024 · ​ ​ ​ · 2023
​ · ​ · (in thousands) · ​
Balance at beginning of year​$12,543​$11,926​$10,443​
Decrease in unrecognized tax benefits as a result of tax positions taken during a prior period​(295)​(330)​(271)​
Decreases in unrecognized tax benefits related to settlements with tax authorities​—​—​—​
Increases in unrecognized tax benefits as a result of tax positions taken during the current period​438​947​1,754​
Balance at end of year​$12,686​$12,543​$11,926​
​​​​​​​​​​​
Recorded as other long-term liability​$9,291​$9,049​$8,344​
Recorded as a decrease in deferred tax assets​3,395​3,494​3,582​
Balance at end of year​$12,686​$12,543​$11,926​

Note 19. Merger

On September 30, 2025, the Company, Victory Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and Veeco Instruments Inc., a Delaware corporation (“Veeco”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub shall be merged with and into Veeco (the “Merger”), with Veeco surviving as a wholly-owned subsidiary of the Company.

At the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.01 per share, of Veeco (“Veeco Common Stock”), issued and outstanding immediately prior to the Effective Time (other than shares that are owned by the Company, Veeco or Merger Sub or any wholly owned subsidiary of the Company, Veeco or Merger Sub) will be converted into the right to receive 0.3575 (the “Exchange Ratio”) newly issued shares of Company common stock (the “Company Common Stock”) (the “Common Stock Merger Consideration”). No fractional shares of the Company will be issued in the Merger, and Veeco stockholders will receive cash in lieu of fractional shares as part of the merger consideration (the “Fractional Shares Cash Amount”, and the Fractional Shares Cash Amount together with the Common Stock Merger Consideration will be referred to as the “Merger Consideration”), as specified in the Merger Agreement.

The Merger Agreement may be terminated upon the mutual written consent of Axcelis and Veeco. In addition, either Axcelis or Veeco may terminate the Merger Agreement in certain circumstances, including if (a) certain governmental entities have issued a final and non-appealable governmental order or enacted a law prohibiting the Merger or making the closing of the Merger illegal, (b) the Merger is not consummated by September 30, 2026, subject to successive automatic extensions until as late as June 30, 2027 if the only remaining conditions to be satisfied are regulatory approvals,

(c) the Axcelis stockholders fail to approve the Company Stock Issuance, (d) the Veeco stockholders fail to adopt the Merger Agreement, (e) the other party is in breach of the Merger Agreement in a manner that would result in a failure of an applicable closing condition (subject to the applicable cure period set forth in the Merger Agreement) or (f) the other party’s board of directors has changed its recommendation with respect to the Merger.

If the Merger Agreement is terminated by a party following a recommendation change of the board of directors of the other party, the non-terminating party will be required to pay the other party the following termination fee: (i) if the non-terminating party is Axcelis, a termination fee of$108.7 million; and (ii) if the non-terminating party is Veeco, a termination fee of$77.5 million. Each party may also be required to pay such termination fee if such party enters into a competing proposal within twelve months of termination of the Merger Agreement under certain circumstances. In addition, if the Merger Agreement is terminated by a party as a result of the other party’s failure to obtain stockholder approval, or is terminated by a party due to the other party’s breach of the Merger Agreement that would result in a failure of an applicable closing condition (subject to the applicable cure period set forth in the Merger Agreement), then the non-terminating party will be required to pay a fixed expense reimbursement amount of$15.0 million.

On February 6, 2026, Axcelis held a special meeting of stockholders (the “Special Meeting”) at which the Company Stock Issuance was approved.

The completion of the Merger remains subject to other customary closing conditions, including the final pending regulatory approval from the State Administration for Market Regulation of the People’s Republic of China. Axcelis and Veeco continue to expect that the Merger will be completed in the second half of 2026.

Schedule II—Valuation and Qualifying Accounts

​​​​​​​​​​​​​​
​ · ​ ​ ​ · Balance at · ​ ​ ​ · Charged to · ​ ​ ​ · ​ · ​ · ​ ​ ​ · Balance at
​ · ​ · Beginning of · ​ · Costs and · ​ · ​ · ​ · ​ · End of
​ · ​ · Period · ​ · Expenses · ​ · Deductions · ​ · Period
Year ended December 31, 2025​​​​​​​​​​​​​
Allowance for doubtful accounts and returns​$—​$—​$—​$—​
Deferred tax valuation allowance​​14,736​​1,265​​—​​16,001​
Year ended December 31, 2024​​​​​​​​​​​​​
Allowance for doubtful accounts and returns​$460​$3,446​$3,906​$—​
Deferred tax valuation allowance​​10,963​​3,773​​—​​14,736​
Year ended December 31, 2023​​​​​​​​​​​​​
Allowance for doubtful accounts and returns​$—​$1,117​​657​$460​
Deferred tax valuation allowance​​8,370​​3,196​​603​​10,963​

Exhibit Index

​
ExhibitNo.​ ​ ​Description
2.1​Agreement and Plan of Merger, dated as September 30, 2025, by and among Axcelis Technologies, Inc., Veeco Instruments Inc. and Victory Merger Sub, Inc. Incorporated by reference to Exhibit 2.1 of the Company’s Form 8-K filed with the Commission on October 1, 2025.
​​​
3.1​Restated Certificate of Incorporation of the Company, filed November 2, 2017. Incorporated by reference to Exhibit 3.1 of the Company’s Form 10-Q filed with the Commission on November 3, 2017.
​​​
3.2​Bylaws of the Company, as amended and restated as of May 11, 2022. Incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the Commission on May 11, 2022.
​​​
3.3​Certificate of Amendment to the Restated Certificate of Incorporation of the Company filed May 9, 2024. Incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the Commission on May 9, 2024.
​​​
4.4​Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934. Incorporated by reference to Exhibit 4.4 of the Company’s Form 10-K for the year ended December 31, 2019 filed with the Commission on March 2, 2020.
​​​
10.1*​Axcelis Technologies, Inc. 2012 Equity Incentive Plan, as amended by the Board of Directors on November 13, 2025. Filed herewith.
​​​
10.2*​Form of Indemnification Agreement approved by the Board of Directors of the Company on February 9, 2012 for use with each of its directors and officers. Incorporated by reference to Exhibit 10.4 of the Company’s report on Form 10-K for the year ended December 31, 2011 filed with the Commission on February 29, 2012.
​​​
10.3*​Form of Change in Control Agreement, as amended, as approved by the Compensation Committee of the Board of Directors on November 11, 2016, between the Company and each of its executive officers. Incorporated by reference to Exhibit 10.6 of the Company’s Form 10-K for the year ended December 31, 2016 filed with the Commission on March 14, 2017.
​​​
10.4*​Form of Employee Non-Qualified Stock Option Certificate under the 2012 Equity Incentive Plan, adopted June 18, 2012. Incorporated by reference to Exhibit 10.2 of the Company’s report on Form 10-Q for the quarter ended June 30, 2012 filed with the Commission on August 7, 2012.
​​​
10.5*​Form of Non-Employee Director Non-Qualified Stock Option Certificate under the 2012 Equity Incentive Plan, adopted June 18, 2012. Incorporated by reference to Exhibit 10.3 of the Company’s report on Form 10-Q for the quarter ended June 30, 2012 filed with the Commission on August 7, 2012.
​​​
10.6*​Form of Restricted Stock Unit Award Agreement under the 2012 Equity Incentive Plan, adopted June 18, 2012. Incorporated by reference to Exhibit 10.4 of the Company’s report on Form 10-Q for the quarter ended June 30, 2012 filed with the Commission on August 7, 2012.
​​​
10.7*​Named Executive Officer Base Compensation at February 14, 2026. Filed herewith.
​​​
10.8*​Non-Employee Director Cash Compensation at February 14, 2026. Filed herewith.
​​​
10.9*​Employment Agreement between the Company and Russell J. Low dated May 11, 2023. Incorporated by reference to Exhibit 10.1 of the Company’s report on Form 8-K filed with the Commission on May 12, 2023.
​​​
10.10*​2023 Amended and Restated Employment Agreement between the Company and Mary G. Puma dated February 24, 2023. Incorporated by reference to Exhibit 10.1 of the Company’s report on Form 8-K filed with the Commission on April 18, 2023.
​​​
​
ExhibitNo.​ ​ ​Description
10.11*​Form of Executive Separation Pay Agreement between the Company and each of its executive officers other than Russell J. Low, including Gerald M. Blumenstock, James G. Coogan, Eileen J. Evans, Gregory F Redinbo and Christopher J. Tatnall, having dates from September 6, 2022 to December 12, 2024. Incorporated by reference to Exhibit 10.2 of the Company’s Form 10-Q for the quarter ended June 30, 2019 filed with the Commission on August 7, 2019.
​​​
10.12​Lease Agreement between the Company and Beverly Property Owner LLC, effective January 30, 2015. Incorporated by reference to Exhibit 10.24 of the Company’s Form 10-K for the year ended December 31, 2014 filed with the Commission on March 11, 2015.
​​​
14.1​Ethical Business Conduct at Axcelis, revised through June, 2015. Filed herewith.
​​​
19.1​Insider Trading Policy, as adopted by the Board of Directors on August 10, 2023. Incorporated by reference to Exhibit 19.1 of the Company’s report on Form 10-K filed with the Commission on February 23, 2024.
​​​
21.1​Subsidiaries of the Company. Filed herewith.
​​​
23.1​Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm. Filed herewith.
​​​
31.1​Certification of the Principal Executive Officer under Exchange Act Rule 13a-14(a)/15d-14(a) (Section 302 of the Sarbanes-Oxley Act), dated February 26, 2026. Filed herewith.
​​​
31.2​Certification of the Principal Financial Officer under Exchange Act Rule 13a-14(a)/15d-14(a) (Section 302 of the Sarbanes-Oxley Act), dated February 26, 2026. Filed herewith.
​​​
32.1​Certification of the Principal Executive Officer pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code (Section 906 of the Sarbanes-Oxley Act), dated February 26, 2026. Filed herewith.
​​​
32.2​Certification of the Principal Financial Officer pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code (Section 906 of the Sarbanes-Oxley Act), dated February 26, 2026. Filed herewith.
​​​
97*​Executive Compensation Clawback Policy, as adopted by the Board of Directors on August 10, 2023. Incorporated by reference to Exhibit 10.14 of the Company’s Form 10-K filed with the Commission on February 23, 2024.
​​​
101​The following materials from the Company’s Form 10-K for the year ended December 31, 2025, formatted in eXtensible Business Reporting Language (XBRL): (i) Consolidated Statements of Operations, (ii) Consolidated Statement of Comprehensive Income (iii) Consolidated Balance Sheets, (iv) Consolidated Statements of Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements.
​​​
104​Cover Page Interactive Data File (formatted as iXBRL and contained in Exhibit 101).
*Indicates a management contract or compensatory plan.

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​​​
​AXCELIS TECHNOLOGIES, INC.
​​​
​​​
​By:/s/ Russell J. Low
​​Russell J. Low,
​​President and Chief Executive Officer
Dated: February 26, 2026​​

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the date indicated.

Signature​ ​ ​Title​ ​ ​Date
​​​​​
/s/ Russell J. Low​Director and Principal Executive Officer​February 26, 2026
Russell J. Low
​​​​​
/s/ James G. Coogan​Principal Accounting and Financial Officer​February 26, 2026
James G. Coogan
​​​​​
/s/ Tzu-Yin Chiu​Director​February 26, 2026
​​
Tzu-Yin Chiu
​​​​​
/s/ Gregory B. Graves​Director​February 26, 2026
Gregory B. Graves
​​​​​
/s/ John T. Kurtzweil​Director​February 26, 2026
John T. Kurtzweil
​​​​​
/s/ Jeanne Quirk​Director​February 26, 2026
Jeanne Quirk
​​​​​
/s/ Necip Sayiner​Director​February 26, 2026
Necip Sayiner​​​​
​​​​​
/s/ Thomas St. Dennis​Director​February 26, 2026
Thomas St. Dennis
​​​​​
/s/ Jorge Titinger​Director​February 26, 2026
Jorge Titinger
​​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.